Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - rasagiline mesilate, quantity: 1.56 mg (equivalent: rasagiline, qty 1 mg) - tablet, uncoated - excipient ingredients: microcrystalline cellulose; maize starch; silicon dioxide; citric acid; pregelatinised starch; purified talc; stearic acid - rasagiline sandoz is indicated for the symptomatic treatment of idiopathic parkinson?s disease (pd) as monotherapy and as adjunct therapy to dopamine agonists or to levodopa.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - rasagiline mesilate, quantity: 1.56 mg (equivalent: rasagiline, qty 1 mg) - tablet - excipient ingredients: maize starch; purified talc; stearic acid; microcrystalline cellulose; pregelatinised maize starch; citric acid monohydrate; colloidal anhydrous silica - rasagiline is indicated for the symptomatic treatment of idiopathic parkinson?s disease (pd) as monotherapy and as adjunct therapy to dopamine agonists or to levodopa.

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - rasagiline mesilate, quantity: 1.56 mg (equivalent: rasagiline, qty 1 mg) - tablet - excipient ingredients: purified talc; maize starch; citric acid monohydrate; microcrystalline cellulose; stearic acid; colloidal anhydrous silica; pregelatinised maize starch - rasagiline is indicated for the symptomatic treatment of idiopathic parkinson?s disease (pd) as monotherapy and as adjunct therapy to dopamine agonists or to levodopa.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - rasagiline mesilate, quantity: 1.56 mg (equivalent: rasagiline, qty 1 mg) - tablet - excipient ingredients: stearic acid; purified talc; mannitol; colloidal anhydrous silica; maize starch; pregelatinised maize starch - rasailine-teva is indicated for the symptomatic treatment of idiopathic parkinson?s disease (pd) as monotherapy and as adjunct therapy to dopamine agonists or to levodopa.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rasagiline mesilate, quantity: 1.56 mg - tablet, uncoated - excipient ingredients: purified talc; stearic acid; citric acid; silicon dioxide; microcrystalline cellulose; pregelatinised maize starch; maize starch - rasagiline is indicated for the symptomatic treatment of idiopathic parkinsons disease (pd) as monotherapy (without concomitant levodopa/decarboxylase inhibitor therapy) or as adjunct therapy (with concomitant levodopa/decarboxylase inhibitor therapy).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rasagiline mesilate, quantity: 1.56 mg - tablet, uncoated - excipient ingredients: citric acid; purified talc; pregelatinised maize starch; silicon dioxide; maize starch; microcrystalline cellulose; stearic acid - rasagiline is indicated for the symptomatic treatment of idiopathic parkinsons disease (pd) as monotherapy (without concomitant levodopa/decarboxylase inhibitor therapy) or as adjunct therapy (with concomitant levodopa/decarboxylase inhibitor therapy).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rasagiline mesilate, quantity: 1.56 mg - tablet, uncoated - excipient ingredients: silicon dioxide; microcrystalline cellulose; stearic acid; purified talc; maize starch; citric acid; pregelatinised maize starch - rasagiline is indicated for the symptomatic treatment of idiopathic parkinsons disease (pd) as monotherapy (without concomitant levodopa/decarboxylase inhibitor therapy) or as adjunct therapy (with concomitant levodopa/decarboxylase inhibitor therapy).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rasagiline mesilate, quantity: 1.56 mg - tablet, uncoated - excipient ingredients: silicon dioxide; pregelatinised maize starch; citric acid; maize starch; stearic acid; microcrystalline cellulose; purified talc - rasagiline is indicated for the symptomatic treatment of idiopathic parkinsons disease (pd) as monotherapy (without concomitant levodopa/decarboxylase inhibitor therapy) or as adjunct therapy (with concomitant levodopa/decarboxylase inhibitor therapy).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rasagiline mesilate, quantity: 1.56 mg (equivalent: rasagiline, qty 1 mg) - tablet - excipient ingredients: citric acid monohydrate; pregelatinised maize starch; purified talc; colloidal anhydrous silica; microcrystalline cellulose; stearic acid; maize starch - rasagiline is indicated for the symptomatic treatment of idiopathic parkinson?s disease (pd) as monotherapy and as adjunct therapy to dopamine agonists or to levodopa.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - rasagiline mesilate, quantity: 1.56 mg (equivalent: rasagiline, qty 1 mg) - tablet - excipient ingredients: stearic acid; purified talc; mannitol; colloidal anhydrous silica; maize starch; pregelatinised maize starch - azilect is indicated for the symptomatic treatment of idiopathic parkinson?s disease (pd) as monotherapy and as adjunct therapy to dopamine agonists or to levodopa.